Nonhuman primate model in clinical modeling of diseases for stem cell therapy
- PMID: 30276291
- PMCID: PMC6126269
- DOI: 10.4103/2394-8108.192524
Nonhuman primate model in clinical modeling of diseases for stem cell therapy
Abstract
Nonhuman primates (NHPs) are alike humans in size, behavior, physiology, biochemistry, and immunology. Given close similarities to humans, the NHP model offers exceptional opportunities to understand the biological mechanisms and translational applications with direct relevance to human conditions. Here, we evaluate the opportunities and limitations of NHPs as animal models for translational regenerative medicine. NHP models of human disease propose exceptional opportunities to advance stem cell-based therapy by addressing pertinent translational concerns related to this research. Nonetheless, the value of these primates must be carefully assessed, taking into account the expense of specialized equipment and requirement of highly specialized staff. Well-designed initial fundamental studies in small animal models are essential before translating research into NHP models and eventually into human trials. In addition, we suggest that applying a directed and collaborative approach, as seen in the evolution of stroke NHP models, will greatly benefit the translation of stem cell therapy in other NHP disease models.
Keywords: Myocardial infarction; Parkinson's disease; STEPS; Type-1 diabetes; nonhuman primate models; stem cell therapy; stroke; translational studies.
Conflict of interest statement
There are no conflicts of interest.
References
-
- Bluemel J, Korte S, Schenck E, Weinbauer G. San Diego, CA: Academic Press; 2015. The Nonhuman Primate in Nonclinical Drug Development and Safety Assessment.
-
- Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, et al. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1979;1:249–54. - PubMed
-
- Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979–80. - PubMed
-
- Bergman H, Raz A, Feingold A, Nini A, Nelken I, Hansel D, et al. Physiology of MPTP tremor. Mov Disord. 1998;13(Suppl 3):29–34. - PubMed
-
- Bédard PJ, Di Paolo T, Falardeau P, Boucher R. Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H] spiperone binding. Brain Res. 1986;379:294–9. - PubMed
